A Phase II Trial of Radiotherapy (RT)-Durvalumab Without Prophylactic Neck Irradiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REWRITe
- Sponsors Groupe Oncologie Radiotherapie Tete et Cou
- 05 Sep 2019 Status changed from not yet recruiting to recruiting.
- 02 Aug 2019 Planned initiation date changed from 1 Feb 2019 to 1 Sep 2019.
- 17 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.